Publications

View and download slide summaries of the latest original articles focusing on therapies in immune-mediated inflammatory diseases including rheumatology, dermatology, and gastroenterology. All materials produced by the team are subsequently reviewed and approved by individual Steering Committee members.

August 2023

A JAK Inhibitor for Treatment of Rheumatoid Arthritis: The Baricitinib Experience

J. Clin. Med. 2023;12(13):4527 doi 10.3390/jcm12134527

Taylor PC,

Laedermann C,

Alten R,

Feist E,

Choy E,

This review by Taylor, et al. reviews the long-term safety and efficacy data for baricitinib. Results from several studies showed that baricitinib has greater efficacy and survival compared to TNF inhibitors, and that the rate of CDAI <10 for baricitinib-treated RA patients increased over the course of seven years. Data also showed that remission rates were higher in real-world evidence than in RCTs.

Keywords:

June 2023

Baixa incapacidade funcional sustentada na espondiloartrite axial (axSpA): Quais são os resultados primários que devem ser visados para atingir esse objetivo?

Arthritis Research & Therapy (2023) 25:70 https://pubmed.ncbi.nlm.nih.gov/37118833/

Walter P. Maksymowych,

Robert D. Inman,

Louis Bessette,

Proton Rahman,

Emmanouil Rampakakis,

Odalis Asin‑Milan,

Meagan Rachich,

Anne Marilise Marrache and Allen J. Lehman

This real-world study showed that sustained BASDAI <3 may be a valid and feasible target for a treat-to-target strategy in AxSpA, having function as treatment goal.

Keywords:

Review

Efeito do índice de massa corporal na resposta ao tratamento com DMARDs biológicos/sintéticos direcionados em pacientes com artrite reumatoide, artrite psoriática ou espondiloartrite axial. Uma revisão sistemática

Autoimmunity Reviews 22 (2023) 103357

Chrysoula G. Gialouri,

Maria Pappa,

Gerasimos Evangelatos,

Elena Nikiphorou,

George E. Fragoulis

The study demonstrated that obesity is a factor that could play a role in treatment decision-making in people living with inflammatory arthritis (IA). It appears that efficacy of TNFi is affected by patients’ weight/BMI in all forms of IA, while this is not the case for TCZ and ABA in RA, as well for IL-17 and IL-23 inhibitors in PsA.

Keywords:

Inibição da interleucina-17 em pacientes com artrite psoriásica oligoarticular

Rheumatol Ther. 2023;10(4):849-860 doi: 10.1007/s40744-023-00548-y

Ogdie A,

Secukinumab reduced disease activity across a range of outcome measures by week 12, with sustained responses through 52 weeks.

Keywords:

Inibidores de JAK e o risco de malignidades: Uma meta-análise com as indicações de tratamento

Ann Rheum Dis. 2023;82(8):1059–1067 doi: 10.1136/ard-2023-224049

Patel V,

Adas MA,

Ng KKH,

Cope AP,

The objective of this study was to estimate the association of JAKi with the incidence of malignancy, compared with placebo, TNFi and MTX.

Keywords:

May 2023

Quando iniciar o tratamento com secukinumabe em pacientes com espondiloartropatia axial: antes ou depois do tratamento com anti-TNFα?

Reumatol Clin. 19 (2023); 175–179 doi 10.1016/j.reumae.2022.03.007

Ak T,

Mustafayeva L,

Celik Y,

Ayla A,

Urgurlu S

Secukinumab, an IL-17A monoclonal antibody, was shown to have remarkable efficacy for axSpA in the MEASURE 2 and MEASURE 3 trials. Previous studies have concluded that secukinumab was more efficacious in TNFi-naïve patients.

Keywords:

April 2023

Incidência de doença pulmonar intersticial em pacientes com artrite reumatoide tratados com medicamentos biológicos e sintéticos direcionados modificadores da doença

JAMA Netw Open. 2023;6(3):e233640 doi: 10.1001/jamanetworkopen.2023.3640

Baker MC,

Liu Y,

Lu R,

Lin J,

Melehani J,

Robinson WH

Retrospective cohort study results suggest that treatment with tofacitinib, and perhaps other JAK inhibitors, may provide a benefit in reducing the risk of developing RA-Interstitial Lung Disease (ILD).

Keywords:

March 2023

Impacto dos AINEs na incidência cumulativa de 8 anos de eventos cardiovasculares graves em pacientes com espondilite anquilosante: Um estudo em nível nacional

Rheumatology (Oxford). 2023 doi: 10.1093/rheumatology/kead072

Fakih O,

Prati C,

MACEs were observed in patients newly receiving compensation from the Long-term Illness Scheme for AS. The objective of this study was to describe the incidence of MACEs in French patients newly benefiting from the French LTI for AS. The study also sought to evaluate the effect of various treatments on the risk of MACE occurrence.

Keywords:

Perfil de Segurança de Upadacitinibe em Mais de 15.000 Pacientes-Ano em Artrite Reumatoide, Artrite Psoriática, Espondilite Anquilosante e Dermatite Atópica

RMD Open. 2023;9(1):e002735 doi: 10.1136/rmdopen-2022-002735

Nash P,

Liu J,

Palac H,

Shaw T,

Mease PJ,

Guttman-Yassky E

Integrated analysis of the safety profile of upadacitinib demonstrates that it was generally well-tolerated in RA, PsA, AS and AD, with no new safety risks identified, compared with previous reports.

Keywords:

Segurança de Baricitinib para Eventos de Interesse Especial em Populações em Risco: Uma análise de dados de ensaios randomizados em indicações reumatológicas e dermatológicas

Adv Ther. 2023;40(4):1867–1883 doi: 10.1007/s12325-023-02445-w

Taylor PC,

Bieber T,

Alten R,

Witte T,

Issa M,

Grond S,

Analysis of pooled data from the baricitinib clinical development programmes finds a low incidence rate of MACE, myocardial infarction, lung cancer, VTE, and overall mortality in patients <65 years without risk factors.